NEW YORK–(BUSINESS WIRE)–Lantern Pharma is applying Artificial Intelligence (AI) to tailor
multiple promising precision drug programs to the right cancer patients
through use of their RADRTM platform (Response Algorithm for
Drug Rescue and Positioning).
Lantern is disrupting the drug development process using seamless
integration of relevant existing data, generation of new clean data
closely modeling real world evidence and very focused AI technology
application to further model this data and distill into meaningful
information that can identify & stratify right patients with high
accuracy. Even a small step ahead in the right direction will be a huge
leap for the pharma industry.
Lantern is currently leading the way in AI directed drug development,
recently having fast tracked shelved assets from in-license to
out-license within 18 months. Lantern is currently progressing 3
clinical stage drugs in using this technology. Lantern aims to develop
10+ precision oncology treatments over the next 2 years by opening up
access to its RADR platform to other pharmaceutical companies.
It is therefore no surprise then that Lantern Pharma will present at the
upcoming AI Pharma Innovation: Clinical Development Summit
to be held in Boston in July 2018. The Conference series is solely
dedicated to accelerating the effective adoption and successful
application of AI and machine learning technologies at specific points
of the pharmaceutical value chain.
Arun Asaithambi said, “Lantern Pharma is delighted to participate in
this upcoming event in Boston. It’s part of a wider recognition we are
receiving as a company leading the way in the AI space, having
successfully deployed this approach and validated it through to
Our Lantern team will also be participating/attending the following
- AACR Annual Meeting, Chicago, IL (April 14 -April 18)
BioWednesday Cambridge: The Role of AI and Big Data in Drug
Discovery, Cambridge, UK (18th April)
World Medical Innovation Forum – Artificial Intelligence,
Boston, MA (April 23-25th)
- BIO2018, Boston, MA (June 4-7th)
AI Pharma Innovation: Clinical Development Summit, Boston, MA
About Lantern Pharma Inc
Lantern Pharma is a late clinical stage precision oncology company that
is using proprietary tech platform called RADR to identify drug specific
complex genetic signatures (potential CDX) for potential responders
identification and stratification with a high prediction accuracy to
conduct focused precision clinical trials. RADR is integrating any
existing clinical data, with data generated from wet-lab approach
closely modeling real world evidence/clinical trials and artificial
intelligence to identify genetic signatures and right responders.
Lantern Pharma Inc has 3 drugs in the pipeline, Irofulven-1
out-licensed, Irofulven-2 (prostate and ovarian) entering clinical
development, Tavocept, a Ph3 NSCLC cancer drug. Lantern is continuously
looking to in-license or acquire or partner drugs programs and RADR
Tech. Lantern also is building a tissue and data access network to
enable the success of the precision programs.
Lantern’s approach can improve success of the drug, lower developmental
costs and time many folds vs traditional drug developmental processes.